about
The pseudokinase MLKL mediates necroptosis via a molecular switch mechanismDynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesionsThe Pseudokinase MLKL and the Kinase RIPK3 Have Distinct Roles in Autoimmune Disease Caused by Loss of Death-Receptor-Induced Apoptosis.MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death.TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKTDifferential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.TRAIL in cancer therapy: present and future challenges.The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice.Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC levelDeath Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells.Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.The molecular relationships between apoptosis, autophagy and necroptosis.Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways.Relevance of necroptosis in cancer.'Did He Who Made the Lamb Make Thee?' New Developments in Treating the 'Fearful Symmetry' of Acute Myeloid Leukemia.Linear ubiquitin chain assembly complex coordinates late thymic T-cell differentiation and regulatory T-cell homeostasis.Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia.dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8.Autophagy and AML--food for thought.P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.The TNF Receptor Superfamily-NF-κB Axis Is Critical to Maintain Effector Regulatory T Cells in Lymphoid and Non-lymphoid Tissues.Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF.RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis.Inhibitor of Apoptosis Proteins (IAPs) Limit RIPK1-Mediated Skin Inflammation.Jekyll & Hyde: The Other Life of the Death Ligand TRAIL.Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.Colony-stimulating factor-1-induced oscillations in phosphatidylinositol-3 kinase/AKT are required for caspase activation in monocytes undergoing differentiation into macrophagesTumor immune evasion arises through loss of TNF sensitivityRecent advances in understanding inhibitor of apoptosis proteinscIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent mannerAntagonism of IAPs Enhances CAR T-cell EfficacyViral MLKL Homologs Subvert Necroptotic Cell Death by Sequestering Cellular RIPK3MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma CellsMutations that prevent caspase cleavage of RIPK1 cause autoinflammatory diseaseTargeting triple-negative breast cancers with the Smac-mimetic birinapantMLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis
P50
Q27685465-E7BDA472-79C4-4BAF-BDFD-92C034C2563EQ28276307-F94F196E-C205-450C-B0FB-57DA3537B083Q33434632-89EF6B29-38B4-4589-9F26-32A5DCC55C4EQ33765641-AE5DB1D5-C924-4B15-B53E-D63A95EB82D0Q33916314-E8962C1D-5707-42D6-99CE-EA9E2D6B68B7Q33999606-9EB161D7-7DEF-4D96-A181-05C7D0449DD4Q34291312-6D7E4B53-58EB-4344-BBA0-DFCB8F7AFF87Q34527239-0106A3B6-C929-4416-8593-BCAD9BA4AC98Q34729606-9D36ACB1-0ABB-4345-A860-4579EF2B95DDQ35051505-72ED1F6E-52D9-428E-A1AD-C42AAF71EFA6Q35641622-BA804153-3C7D-430B-9EF1-E5DB99AC0B6DQ35643014-ABC615AB-3AF2-4C1C-921A-5258CFB21ADDQ38367402-10A41E69-DDC5-4CED-98B3-C951B6A7FAC2Q39010178-4A1DCF28-E7A5-4C31-AD7D-00123F9E1DBDQ39030578-B9CE8779-A915-4648-9872-14CFAF6B1B4DQ39135350-B5A34E19-A3B8-4B1E-912E-B0ADA0680B55Q39179203-FBD24174-656B-49E8-80B7-CD586ECB3179Q39292054-C88FE65B-F7E0-4DCC-8163-E81ED8011087Q39378876-872FA0EC-A555-4718-90FC-0473E486679EQ39739470-389F7843-AB1E-4CEE-857E-2403069E714BQ40001770-1843B8FC-CA1E-45B6-B222-07F8AB17AE37Q40058481-E2BCFDA4-A108-4215-A380-F85027F33428Q47741752-399A8F87-0945-4E20-A620-469DDFCF21D2Q50552396-8FECD465-6D03-477E-A41C-637FBA460D50Q50663781-E495E6AD-0683-4BEC-BCB3-A7AAEDDA35BCQ50925867-71CE9DD1-32C9-42FD-937C-0466EB5F6BA3Q51133244-CA6F1576-217F-4803-A2D5-5B6E2DD49CB2Q52885510-D1982384-8EA9-4B8B-B985-6D1D8166522BQ57219993-B7996A07-527E-48BD-B49C-20A9EC4B3386Q57272424-D6078939-4CB1-44C3-A364-C6F3569F4C60Q60920665-B9A6D8F4-4D05-4EEC-AD91-2181F0053DC1Q62817637-A0447455-60CA-4543-B421-16EC90054920Q62819680-86D61287-52ED-4734-95DB-264FF92D6ACFQ90281552-D36D7955-C4CA-47A1-A9A9-7B117C887835Q90308707-318961CC-B2D3-46C9-97B5-DDC604624031Q91892511-081E9522-0C21-4435-942B-860C402232D7Q93270509-716329FE-C4E3-4666-AD28-1BF07349255CQ96609364-E52CD8CE-C844-4C01-9565-B9920A93E057
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Najoua Lalaoui
@ast
Najoua Lalaoui
@en
Najoua Lalaoui
@es
Najoua Lalaoui
@nl
Najoua Lalaoui
@sl
type
label
Najoua Lalaoui
@ast
Najoua Lalaoui
@en
Najoua Lalaoui
@es
Najoua Lalaoui
@nl
Najoua Lalaoui
@sl
prefLabel
Najoua Lalaoui
@ast
Najoua Lalaoui
@en
Najoua Lalaoui
@es
Najoua Lalaoui
@nl
Najoua Lalaoui
@sl
P1053
C-1410-2014
P106
P21
P31
P3829
P496
0000-0002-0165-3324